A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines

被引:5
|
作者
Wu, KM
D'Amico, M
Wang, CG
Albanese, C
Pestell, RG
Mani, S
机构
[1] Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
[3] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA
[4] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA
关键词
HeLa cells; IAP; survivin; caspases; UCN-01; flavopiridol;
D O I
10.1007/s10637-005-1438-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Flavopiridol and UCN-01 are two novel protein kinase inhibitors with diverse cellular effects that may complement each other with regards to induction of apoptosis. HeLa cells engineered to overexpress human survivin (HeLa-S) were at least 4.8-fold resistant to UCN-01 relative to proliferation observed in control HeLa cells (HeLa-V). Flavopiridol cytotoxicity as measured using the MTT assay was unaffected in HeLa-S cells when compared with HeLa-V cells. Similarly, simultaneous treatment of HeLa-V cells with flavopiridol and UCN-01 for 72 hours did not result in synergistic inhibition of proliferation; however, in HeLa-S cells, this combination resulted in synergistic inhibition of cell proliferation. Flavopiridol and UCN-01 augmented apoptosis in HeLa-S cells (as compared with HeLa-V cells) as measured by caspase-3 cellular activity assay, DNA fragmentation and PARP cleavage by western blot. In HeLa-V and -S cells, combination treatment resulted in caspase-8 cleavage. Caspase-9 was expressed in HeLa-V cells; however, there was a marked reduction of caspase-9 content in HeLa-S cells only. Combination treatment resulted in a significant reduction in survivin abundance in HeLa-S and SKBR3-UR cells, but not in their respective parental lines. The synergy of Flavopiridol and UCN-01 are selectively toxic to survivin-overexpressing cell lines and the mechanism of toxicity involves caspase-dependent cell death.
引用
收藏
页码:299 / 309
页数:11
相关论文
共 50 条
  • [21] Phase I study combining UCN-01 with irinotecan in resistant solid tumor malignancies.
    Fracasso, PM
    Rudek, MA
    Naughton, MJ
    Picus, J
    Rader, JS
    Chen, RC
    Fears, CL
    Goodner, SA
    Dancey, J
    McLeod, HL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 229S - 229S
  • [22] Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines
    Ema, Y.
    Igase, M.
    Takeda, Y.
    Yanase, T.
    Umeki, S.
    Hiraoka, H.
    Okuda, M.
    Mizuno, T.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2016, 14 : 95 - 106
  • [23] A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors
    Dees, EC
    Baker, SD
    O'Reilly, S
    Rudek, MA
    Davidson, SB
    Aylesworth, C
    Elza-Brown, K
    Carducci, MA
    Donehower, RC
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 664 - 671
  • [24] Regulation of UCN-01 induced mitotic cell death by pro- and anti-apoptotic pathways
    Vogel, Celia
    Hager, Christian
    Bastians, Holger
    EJC SUPPLEMENTS, 2006, 4 (06): : 16 - 17
  • [25] Comparison of UCN-01 and a novel cell cycle checkpoint inhibitor: similarities and differences in their mechanism of action.
    Kohn, EA
    Blank, DH
    Gribble, GW
    Eastman, A
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3792S - 3792S
  • [26] 7-hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines
    Xiao, HH
    Makeyev, Y
    Butler, J
    Vikram, B
    Franklin, WA
    RADIATION RESEARCH, 2002, 158 (01) : 84 - 93
  • [27] Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01
    Amornphimoltham, P
    Sriuranpong, V
    Patel, V
    Benavides, F
    Conti, CJ
    Sauk, J
    Sausville, EA
    Molinolo, AA
    Gutkind, JS
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4029 - 4037
  • [28] UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response
    Kruger, EA
    Blagosklonny, MV
    Dixon, SC
    Figg, WD
    INVASION & METASTASIS, 1999, 18 (04): : 209 - 218
  • [29] A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
    Ma, Cynthia X.
    Ellis, Matthew J. C.
    Petroni, Gina R.
    Guo, Zhanfang
    Cai, Shi-rong
    Ryan, Christine E.
    Lockhart, A. Craig
    Naughton, Michael J.
    Pluard, Timothy J.
    Brenin, Christiana M.
    Picus, Joel
    Creekmore, Allison N.
    Mwandoro, Tibu
    Yarde, Erin R.
    Reed, Jerry
    Ebbert, Mark
    Bernard, Philip S.
    Watson, Mark
    Doyle, Laurence A.
    Dancey, Janet
    Piwnica-Worms, Helen
    Fracasso, Paula M.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 483 - 492
  • [30] Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines
    Playle, LC
    Hicks, DJ
    Qualtrough, D
    Paraskeva, C
    BRITISH JOURNAL OF CANCER, 2002, 87 (03) : 352 - 358